drugset
drugset / Trial / NCT02810964

Sulforaphane to Reduce Symptoms of Schizophrenia

NCT02810964 ↗

Phase 2 Completed 64 enrolled Sheppard Pratt Health System
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.

Timeline

Start
2017-02-22
Primary completion
2019-11-11
Completion
2019-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulforaphane Small molecule 0.1 mmol Oral

Indications

schizoaffective disorder schizophrenia